BACKGROUND: There is conflicting evidence regarding reliability criteria for the controlled attenuation parameter (CAP; a marker for hepatic steatosis [HS]). Thus, we assessed the diagnostic performance of CAP according to different reliability criteria based on real-world data from an academic centre. METHODS: Patients undergoing measurement of CAP and liver biopsy (±6 months) at the Medical University of Vienna were included. HS was assessed according to SAF score. RESULTS: In total 319 patients were included. The main aetiologies were non-alcoholic fatty liver disease (NAFLD, n = 177, 55.5%), viral hepatitis (n = 49, 15.4%), and alcoholic liver disease (ALD, n = 29, 9.1%). Histological steatosis and fibrosis stages were: S0: 93 (29.2%), S1: 100 (31.3%), S2: 67 (21.0%), and S3: 59 (18.5%); F0/F1: 150 (47.0%), F2: 47 (14.7%), and F3/F4: 122 (48.3%). In the overall cohort, the area under the receiver operating characteristic curve (AUC) of CAP was 0.843 (95% confidence interval [CI]: 0.798-0.887) for diagnosing HS ≥ S1), 0.789 (95%CI: 0.740-0.839) for ≥S2, and 0.767 (95%CI: 0.712-0.823) for S3. CAP corrections as suggested by Karlas et al. did not improve the diagnostic performance. Importantly, the AUC of CAP for HS ≥ S1 was numerically highest in patients with CAP-IQR/median<0.10 or <0.20 (obtained in 37.9% and 74.9%), in whom CAP also had better diagnostic performance, as compared with patients not meeting these criteria. Moreover, it was substantially higher in 288 (90.3%) patients with CAP-IQR/median<0.3: 0.856 (95%CI: 0.809-0.903) vs. patients not meeting this criterion (0.530 [95%CI: 0.309-0.751]). In contrast, the previously suggested reliability criterion of CAP-IQR<40 dB/m was not associated with an improved diagnostic performance for HS≥S1 (0.866 [95%CI: 0.812-0.920] vs. 0.799 [95%CI: 0.717-0.881]) and was only obtained in 199 (62.4%) patients. CONCLUSION: CAP-IQR/median<0.1, <0.2, and <0.3 identify reliable measurements for diagnosing any hepatic steatosis (≥S1). Importantly, CAP-IQR/median<0.3 has a considerably higher applicability in clinical practice, as compared with the previously suggested CAP-IQR<40 dB/m criterion.
BACKGROUND: There is conflicting evidence regarding reliability criteria for the controlled attenuation parameter (CAP; a marker for hepatic steatosis [HS]). Thus, we assessed the diagnostic performance of CAP according to different reliability criteria based on real-world data from an academic centre. METHODS:Patients undergoing measurement of CAP and liver biopsy (±6 months) at the Medical University of Vienna were included. HS was assessed according to SAF score. RESULTS: In total 319 patients were included. The main aetiologies were non-alcoholic fatty liver disease (NAFLD, n = 177, 55.5%), viral hepatitis (n = 49, 15.4%), and alcoholic liver disease (ALD, n = 29, 9.1%). Histological steatosis and fibrosis stages were: S0: 93 (29.2%), S1: 100 (31.3%), S2: 67 (21.0%), and S3: 59 (18.5%); F0/F1: 150 (47.0%), F2: 47 (14.7%), and F3/F4: 122 (48.3%). In the overall cohort, the area under the receiver operating characteristic curve (AUC) of CAP was 0.843 (95% confidence interval [CI]: 0.798-0.887) for diagnosing HS ≥ S1), 0.789 (95%CI: 0.740-0.839) for ≥S2, and 0.767 (95%CI: 0.712-0.823) for S3. CAP corrections as suggested by Karlas et al. did not improve the diagnostic performance. Importantly, the AUC of CAP for HS ≥ S1 was numerically highest in patients with CAP-IQR/median<0.10 or <0.20 (obtained in 37.9% and 74.9%), in whom CAP also had better diagnostic performance, as compared with patients not meeting these criteria. Moreover, it was substantially higher in 288 (90.3%) patients with CAP-IQR/median<0.3: 0.856 (95%CI: 0.809-0.903) vs. patients not meeting this criterion (0.530 [95%CI: 0.309-0.751]). In contrast, the previously suggested reliability criterion of CAP-IQR<40 dB/m was not associated with an improved diagnostic performance for HS≥S1 (0.866 [95%CI: 0.812-0.920] vs. 0.799 [95%CI: 0.717-0.881]) and was only obtained in 199 (62.4%) patients. CONCLUSION: CAP-IQR/median<0.1, <0.2, and <0.3 identify reliable measurements for diagnosing any hepatic steatosis (≥S1). Importantly, CAP-IQR/median<0.3 has a considerably higher applicability in clinical practice, as compared with the previously suggested CAP-IQR<40 dB/m criterion.
Authors: Veeral Ajmera; Charlie C Park; Cyrielle Caussy; Seema Singh; Carolyn Hernandez; Ricki Bettencourt; Jonathan Hooker; Ethan Sy; Cynthia Behling; Ronghui Xu; Michael S Middleton; Mark A Valasek; Claire Faulkner; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba Journal: Gastroenterology Date: 2018-04-13 Impact factor: 22.682
Authors: Gioacchino Leandro; Alessandra Mangia; Jason Hui; Paolo Fabris; Laura Rubbia-Brandt; Guido Colloredo; Luigi E Adinolfi; Tarik Asselah; Julie R Jonsson; Antonina Smedile; Norah Terrault; Valerio Pazienza; Maria Teresa Giordani; Emiliano Giostra; Aurelio Sonzogni; Giuseppe Ruggiero; Patrick Marcellin; Elizabeth E Powell; Jacob George; Francesco Negro Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Thomas Karlas; David Petroff; Magali Sasso; Jian-Gao Fan; Yu-Qiang Mi; Victor de Lédinghen; Manoj Kumar; Monica Lupsor-Platon; Kwang-Hyub Han; Ana C Cardoso; Giovanna Ferraioli; Wah-Kheong Chan; Vincent Wai-Sun Wong; Robert P Myers; Kazuaki Chayama; Mireen Friedrich-Rust; Michel Beaugrand; Feng Shen; Jean-Baptiste Hiriart; Shiv K Sarin; Radu Badea; Kyu Sik Jung; Patrick Marcellin; Carlo Filice; Sanjiv Mahadeva; Grace Lai-Hung Wong; Pam Crotty; Keiichi Masaki; Joerg Bojunga; Pierre Bedossa; Volker Keim; Johannes Wiegand Journal: J Hepatol Date: 2016-12-28 Impact factor: 25.083
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Wai-Kay Seto; Rex W H Hui; Lung-Yi Mak; James Fung; Ka-Shing Cheung; Kevin S H Liu; Danny Ka-Ho Wong; Ching-Lung Lai; Man-Fung Yuen Journal: Clin Gastroenterol Hepatol Date: 2017-09-29 Impact factor: 11.382
Authors: Georg Semmler; Lorenz Balcar; Hannes Oberkofler; Stephan Zandanell; Michael Strasser; David Niederseer; Alexandra Feldman; Felix Stickel; Pavel Strnad; Christian Datz; Bernhard Paulweber; Elmar Aigner Journal: J Pers Med Date: 2021-03-01